HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever/ivillage.com

This article was originally published in The Rose Sheet

Executive Summary

Substance.com beauty site to launch late spring under joint venture agreement, the companies announce Oct. 18. Substance.com will replace ivillage's existing Beauty Channel with deeper, more personalized editorial content and expert advice. Substance.com, headquartered in ivillage.com's New York City office, is headed by CEO Sanjeev Mehara, Unilever's former North American finance head for personal wash, skin and oral care. Alan Gravely serves as VP-business management. The joint venture was announced in February (1"The Rose Sheet" Feb. 21, p. 7). Substance.com is expected to be profitable three years after launch

Substance.com beauty site to launch late spring under joint venture agreement, the companies announce Oct. 18. Substance.com will replace ivillage's existing Beauty Channel with deeper, more personalized editorial content and expert advice. Substance.com, headquartered in ivillage.com's New York City office, is headed by CEO Sanjeev Mehara, Unilever's former North American finance head for personal wash, skin and oral care. Alan Gravely serves as VP-business management. The joint venture was announced in February (1 (Also see "Unilever/ivillage Web Venture To Offer "Unbiased," Personalized Beauty Info" - HBW Insight, 21 Feb, 2000.)). Substance.com is expected to be profitable three years after launch.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel